Found: 7
Select item for more details and to access through your institution.
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2021, v. 78, n. 3, p. 285, doi. 10.1001/jamaneurol.2020.4607
- By:
- Publication type:
- Article
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program.
- Published in:
- Epilepsia (Series 4), 2023, v. 64, n. 8, p. e156, doi. 10.1111/epi.17665
- By:
- Publication type:
- Article
Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials.
- Published in:
- Epilepsia (Series 4), 2023, v. 64, n. 7, p. 1812, doi. 10.1111/epi.17618
- By:
- Publication type:
- Article
Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program.
- Published in:
- Epilepsia (Series 4), 2023, v. 64, n. 3, p. 619, doi. 10.1111/epi.17496
- By:
- Publication type:
- Article
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.
- Published in:
- Epilepsia (Series 4), 2022, v. 63, n. 5, p. 1189, doi. 10.1111/epi.17199
- By:
- Publication type:
- Article
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial.
- Published in:
- Epilepsia (Series 4), 2022, v. 63, n. 2, p. 426, doi. 10.1111/epi.17150
- By:
- Publication type:
- Article